Clinical and Histopathological Risk Factors for Radioactive Iodine–Refractory Follicular and Oncocytic Thyroid Carcinoma
Authors' conclusion
To our knowledge, this is the first study that correlates clinical and histopathological risk factors with RAI-refractory disease in FTC and OTC, facilitated by a histopathological revision. In FTC, risk factors for RAI-refractory disease were foremost histopathological characteristics of the primary tumor, whereas in OTC presentation with lymph node and distant metastasis was associated with RAI-refractory disease. Our data can help clinical decision-making, particularly in patients at risk for RAI-refractory disease.
Study context
- Population
- Adult FTC and oncocytic thyroid carcinoma (OTC) patients treated at Erasmus MC (the Netherlands), 2000–2016
- Participants
- 90 vs 52
- Exposure
- Risk factors for radioactive iodine (RAI)-refractory disease, stratified by histological subtype (FTC vs OTC)
- FTCn = 90
- OTCn = 52
- Outcome
- RAI-refractory disease (2015 ATA guidelines); risk factors by logistic regression
- Follow-up
- 8.5 years
Methodological detailssingle-centre, histopathological revision (2022 WHO Classification)
- Single-centre
- Histopathological revision (2022 WHO Classification)
Main finding
As reported in the abstract
Observational data: associations, not effects.
Further findings
RAI cycles before RAI-refractory disease
10-year disease-specific survival with RAI-refractory disease
RAI cycles before RAI-refractory disease
- RAI-refractory disease occurred in OTC after fewer cycles than in FTC
10-year disease-specific survival with RAI-refractory disease
- RAI-refractory disease substantially decreased 10-year disease-specific survival, especially in OTC
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →